Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Management issues of congenital adrenal hyperplasia during the transition from pediatric to adult care

  • Choi, Jin-Ho (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoo, Han-Wook (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2015.11.20
  • 심사 : 2016.02.13
  • 발행 : 2017.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Steroid 21-hydroxylase deficiency is the most prevalent form of congenital adrenal hyperplasia (CAH), accounting for approximately 95% of cases. With the advent of newborn screening and hormone replacement therapy, most children with CAH survive into adulthood. Adolescents and adults with CAH experience a number of complications, including short stature, obesity, infertility, tumor, osteoporosis, and reduced quality of life. Transition from pediatric to adult care and management of long-term complications are challenging for both patients and health-care providers. Psychosocial issues frequently affect adherence to glucocorticoid treatment. Therefore, the safe transition of adolescents to adult care requires regular follow-up of patients by a multidisciplinary team including pediatric and adult endocrinologists. The major goals for management of adults with 21-hydroxylase deficiency are to minimize the long-term complications of glucocorticoid therapy, reduce hyperandrogenism, prevent adrenal or testicular adrenal rest tumors, maintain fertility, and improve quality of life. Optimized medical or surgical treatment strategies should be developed through coordinated care, both during transition periods and throughout patients' lifetimes. This review will summarize current knowledge on the management of adults with CAH, and suggested appropriate approaches to the transition from pediatric to adult care.

키워드

참고문헌

  1. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003;349:776-88. https://doi.org/10.1056/NEJMra021561
  2. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133-60. https://doi.org/10.1210/jc.2009-2631
  3. Auchus RJ. Management considerations for the adult with congenital adrenal hyperplasia. Mol Cell Endocrinol 2015;408:190-7. https://doi.org/10.1016/j.mce.2015.01.039
  4. Merke DP, Poppas DP. Management of adolescents with congenital adrenal hyperplasia. Lancet Diabetes Endocrinol 2013;1:341-52. https://doi.org/10.1016/S2213-8587(13)70138-4
  5. Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. Eur J Endocrinol 2004;151 Suppl 3:U77-82.
  6. Kruse B, Riepe FG, Krone N, Bosinski HA, Kloehn S, Partsch CJ, et al. Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 2004;112:343-55. https://doi.org/10.1055/s-2004-821013
  7. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001;138:26-32. https://doi.org/10.1067/mpd.2001.110527
  8. White PC, Speiser PW. Long-term consequences of childhoodonset congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2002;16:273-88. https://doi.org/10.1053/beem.2002.0198
  9. Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008;93:653-60. https://doi.org/10.1210/jc.2007-2417
  10. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110-21. https://doi.org/10.1210/jc.2010-0917
  11. Volkl TM, Simm D, Beier C, Dorr HG. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006;117:e98-105. https://doi.org/10.1542/peds.2005-1005
  12. Volkl TM, Simm D, Korner A, Rascher W, Kiess W, Kratzsch J, et al. Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency? Eur J Endocrinol 2009;160:239-47. https://doi.org/10.1530/EJE-08-0770
  13. Volkl TM, Simm D, Dotsch J, Rascher W, Dorr HG. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4888-95. https://doi.org/10.1210/jc.2006-1069
  14. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003;149:273-85.
  15. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992;74: 685-9.
  16. Nermoen I, Rorvik J, Holmedal SH, Hykkerud DL, Fougner KJ, Svartberg J, et al. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 2011;75:753-9. https://doi.org/10.1111/j.1365-2265.2011.04151.x
  17. Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 2008;89:597-601. https://doi.org/10.1016/j.fertnstert.2007.03.051
  18. Stikkelbroeck NM, Hermus AR, Suliman HM, Jager GJ, Otten BJ. Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and followup investigation after 2.6 years. J Pediatr Endocrinol Metab 2004;17:645-53.
  19. Jin HY, Choi JH, Kim GH, Lee CS, Yoo HW. Testicular adrenal rest tumors in a patient with untreated congenital adrenal hyperplasia. Korean J Pediatr 2011;54:137-40. https://doi.org/10.3345/kjp.2011.54.3.137
  20. Claahsen-van der Grinten HL, Stikkelbroeck NM, Sweep CG, Hermus AR, Otten BJ. Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2006;19:677-85.
  21. Holmes-Walker DJ, Conway GS, Honour JW, Rumsby G, Jacobs HS. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1995;43:291-6. https://doi.org/10.1111/j.1365-2265.1995.tb02034.x
  22. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994;79:1328-33.
  23. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, Schreuders-Bais CA, Feitz WF, Rieu PN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. J Pediatr Adolesc Gynecol 2003;16:289-96. https://doi.org/10.1016/S1083-3188(03)00155-4
  24. Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997;46:327-32. https://doi.org/10.1046/j.1365-2265.1997.1360962.x
  25. Alizai NK, Thomas DF, Lilford RJ, Batchelor AG, Johnson N. Feminizing genitoplasty for congenital adrenal hyperplasia: what happens at puberty? J Urol 1999;161:1588-91. https://doi.org/10.1016/S0022-5347(05)68986-0
  26. Bidet M, Bellanne-Chantelot C, Galand-Portier MB, Golmard JL, Tardy V, Morel Y, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2010;95:1182-90. https://doi.org/10.1210/jc.2009-1383
  27. Tiitinen A, Valimaki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. J Clin Endocrinol Metab 2002;87:2442-5. https://doi.org/10.1210/jcem.87.6.8616
  28. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009;94:1665-70. https://doi.org/10.1210/jc.2008-1414
  29. Bouvattier C, Esterle L, Renoult-Pierre P, de la Perriere AB, Illouz F, Kerlan V, et al. Clinical outcome, hormonal status, gonadotrope axis, and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. A French National Survey. J Clin Endocrinol Metab 2015;100:2303-13. https://doi.org/10.1210/jc.2014-4124
  30. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 1995; 237:439-47. https://doi.org/10.1111/j.1365-2796.1995.tb00868.x
  31. Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008;158:879-87. https://doi.org/10.1530/EJE-07-0887
  32. Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjold A, Hagenfeldt K, et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:4643-9. https://doi.org/10.1210/jc.2007-0744
  33. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997;82:3926-9. https://doi.org/10.1210/jcem.82.12.4320
  34. Gussinye M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibanez L, et al. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997;100:671-4. https://doi.org/10.1542/peds.100.4.671
  35. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013;98:2645-55. https://doi.org/10.1210/jc.2013-1440
  36. Martinerie L, Viengchareun S, Delezoide AL, Jaubert F, Sinico M, Prevot S, et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology 2009;150:4414-24. https://doi.org/10.1210/en.2008-1498
  37. Reisch N. Substitution therapy in adult patients with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2015;29:33-45. https://doi.org/10.1016/j.beem.2014.11.002
  38. Casteras A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009;70:833-7. https://doi.org/10.1111/j.1365-2265.2009.03563.x
  39. Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30:207-29. https://doi.org/10.1016/S0889-8529(08)70027-6
  40. Ogilvie CM, Crouch NS, Rumsby G, Creighton SM, Liao LM, Conway GS. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol (Oxf) 2006;64:2-11. https://doi.org/10.1111/j.1365-2265.2005.02410.x
  41. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav 2004;33:97-104. https://doi.org/10.1023/B:ASEB.0000014324.25718.51
  42. Berenbaum SA, Duck SC, Bryk K. Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase -deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:727-33.
  43. Berenbaum SA. Cognitive function in congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001;30:173-92. https://doi.org/10.1016/S0889-8529(08)70025-2
  44. Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003;88: 1102-6. https://doi.org/10.1210/jc.2002-020782
  45. Gastaud F, Bouvattier C, Duranteau L, Brauner R, Thibaud E, Kutten F, et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007;92:1391-6. https://doi.org/10.1210/jc.2006-1757
  46. Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, et al. Guidelines for the Development of comprehensive care centers for congenital adrenal hyperplasia: guidance from the CARES foundation initiative. Int J Pediatr Endocrinol 2010;2010:275213. https://doi.org/10.1186/1687-9856-2010-275213
  47. Hargitai G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, et al. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. Horm Res 2001;55:161-71.
  48. Muirhead S, Sellers EA, Guyda H; Canadian Pediatric Endocrine Group. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 2002;141:247-52. https://doi.org/10.1067/mpd.2002.126601
  49. Pinto G, Tardy V, Trivin C, Thalassinos C, Lortat-Jacob S, Nihoul-Fekete C, et al. Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management. J Clin Endocrinol Metab 2003;88:2624-33. https://doi.org/10.1210/jc.2002-021433
  50. Nermoen I, Bronstad I, Fougner KJ, Svartberg J, Oksnes M, Husebye ES, et al. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012;167:507-16. https://doi.org/10.1530/EJE-12-0196

피인용 문헌

  1. Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia vol.178, pp.4, 2018, https://doi.org/10.1530/eje-17-0895
  2. Pubertad precoz por hiperplasia adrenal congénita. Reporte de caso vol.68, pp.1, 2017, https://doi.org/10.15446/revfacmed.v68n1.72674